SCHEMBL30876940

SCHEMBL30876940

CCCC(C(N)=O)c1cccc2c1C(=O)NC2=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.43
ALDH1A1 P00352 5/20 0.43
GAA P10253 2/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GSK3B P49841 2/20 0.38
GSK3A P49840 1/20 0.38
CDK5 Q00535 1/20 0.38
CDK5R1 Q15078 1/20 0.38
CASP3 P42574 8/20 0.38
CHEK1 O14757 1/20 0.35
MEN1 O00255 2/20 0.34
POLB P06746 2/20 0.34
KMT2A Q03164 2/20 0.34
KEAP1 Q14145 2/20 0.34
NFE2L2 Q16236 1/20 0.34
HTT P42858 1/20 0.34
CASP2 P42575 2/20 0.33
CASP7 P55210 2/20 0.33
CASP6 P55212 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1256987 0.77 KDM4E (0.40) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL2760791 0.77 ELANE (0.40) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL9136212 0.75 ALDH1A1 (0.38) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL15942346 0.74 ALDH1A1 (0.47) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL10384426 0.74 KDM4E (0.40) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL23142622 0.74 KDM4E (0.42) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL15942344 0.73 CASP3 (0.50) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL8074204 0.73 POLB (0.37) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL6033869 0.72 KDM4E (0.38) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL10731506 0.72 CYSLTR2 (0.39) KDM4EALDH1A1GAAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4611798-A1 METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY CELGENE CORPORATION (US) 2025-09-10 EP disclosed
WO-2024097905-A1 METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY CELGENE CORPORATION (US) 2024-05-10 WO disclosed